Scholarlink

Background <p>Agouti-related protein (AgRP) is an orexigenic neuropeptide that also plays a role in stereotypic behaviors and cognitive impairments. This study examined whether plasma AgRP levels are associated with eating disorder symptom severity and longitudinal symptom changes in anorexia nervosa (AN).</p> Methods <p>This study included 53 drug-naïve patients diagnosed with AN, comprising 41 with the restricting subtype (AN-R) and 12 with the binge/purging subtype (AN-BP), along with 43 healthy controls (HC). At baseline, all participants underwent fasting blood sampling for plasma AgRP measurement and completed the Eating Disorder Examination Questionnaire, Version 6 (EDE-Q). During the 6-month follow-up, patients received routine clinical treatment, and 32 patients underwent repeat AgRP measurement and clinical reassessment. Baseline variables were compared using Mann-Whitney U tests for two-group comparisons or Kruskal-Wallis tests for three-group comparisons, with Bonferroni correction applied for post-hoc analyses. Changes between baseline and follow-up were assessed using the Wilcoxon signed-rank test. Associations between AgRP levels and clinical measures were examined using Spearman correlation and linear regression analyses, with Bonferroni correction applied for multiple comparisons.</p> Results <p>The study found elevated plasma AgRP concentrations in patients with AN, with post hoc analyses indicating higher levels in AN-R compared with HC, while no significant differences were observed between AN-R and AN-BP or between AN-BP and HC. During the 6-month follow-up, AgRP concentrations in patients with AN declined and approached levels observed in HC. Among the 32 patients with AN who completed follow-up, baseline AgRP levels were negatively correlated with follow-up EDE-Q total scores. Body mass index (BMI) was negatively correlated with AgRP levels in all participants. Partial correlation, controlling for baseline BMI, showed that changes in AgRP were positively correlated with improvements in EDE-Q total scores. This association remained significant in regression analysis after adjusting for BMI.</p> Conclusions <p>AgRP levels were elevated in patients with AN at baseline and decreased to levels comparable with HC during treatment, with the magnitude of reduction associated with improvements in EDE-Q total scores. These findings suggest that dynamic changes in AgRP may serve as a biological correlate of the metabolic and clinical recovery process in AN.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Changes in agouti-related protein and symptom improvement in drug-naïve Chinese female patients with anorexia nervosa: a 6-month real-world longitudinal study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月25日

查看全文
  • Yanran Hu,
  • Qing Kang,
  • Chen Chen,
  • Sufang Pang,
  • Yan Chen,
  • Yang Yang,
  • Han Chen,
  • Lei Guo,
  • Jue Chen

摘要

Background

Agouti-related protein (AgRP) is an orexigenic neuropeptide that also plays a role in stereotypic behaviors and cognitive impairments. This study examined whether plasma AgRP levels are associated with eating disorder symptom severity and longitudinal symptom changes in anorexia nervosa (AN).

Methods

This study included 53 drug-naïve patients diagnosed with AN, comprising 41 with the restricting subtype (AN-R) and 12 with the binge/purging subtype (AN-BP), along with 43 healthy controls (HC). At baseline, all participants underwent fasting blood sampling for plasma AgRP measurement and completed the Eating Disorder Examination Questionnaire, Version 6 (EDE-Q). During the 6-month follow-up, patients received routine clinical treatment, and 32 patients underwent repeat AgRP measurement and clinical reassessment. Baseline variables were compared using Mann-Whitney U tests for two-group comparisons or Kruskal-Wallis tests for three-group comparisons, with Bonferroni correction applied for post-hoc analyses. Changes between baseline and follow-up were assessed using the Wilcoxon signed-rank test. Associations between AgRP levels and clinical measures were examined using Spearman correlation and linear regression analyses, with Bonferroni correction applied for multiple comparisons.

Results

The study found elevated plasma AgRP concentrations in patients with AN, with post hoc analyses indicating higher levels in AN-R compared with HC, while no significant differences were observed between AN-R and AN-BP or between AN-BP and HC. During the 6-month follow-up, AgRP concentrations in patients with AN declined and approached levels observed in HC. Among the 32 patients with AN who completed follow-up, baseline AgRP levels were negatively correlated with follow-up EDE-Q total scores. Body mass index (BMI) was negatively correlated with AgRP levels in all participants. Partial correlation, controlling for baseline BMI, showed that changes in AgRP were positively correlated with improvements in EDE-Q total scores. This association remained significant in regression analysis after adjusting for BMI.

Conclusions

AgRP levels were elevated in patients with AN at baseline and decreased to levels comparable with HC during treatment, with the magnitude of reduction associated with improvements in EDE-Q total scores. These findings suggest that dynamic changes in AgRP may serve as a biological correlate of the metabolic and clinical recovery process in AN.